Fred Hutch’s Post

What if you could identify and engage exact physicians with a biomarker positive patient within hours of a patient testing positive? Would this help increase your testing rate? Our Clinical Practice Gaps study, published in the JCO Precision Oncology in 2022* revealed that approximately 64% of potentially eligible patients are lost due to gaps in clinical practice along the patient journey. A significant factor in these missed treatment opportunities is the low prevalence of biomarker testing, often linked to insufficient physician awareness. DXRX Physician Engage enables you to deliver timely, relevant and real-world data-driven messages to physicians treating therapy-eligible patients in as little as 24 hours, educating them on your therapy within the critical treatment decision timeframe, leading to increased biomarker testing rates. Don’t miss the critical window of engagement – talk to us about Physician Engage today. Learn more here: https://lnkd.in/dZNqWKgE *(Sadik et al., JCO 2022) #PrecisionMedicine #BetterTesingBetterTreatment

Dr. Joseph Mikhael, IMF Chief Medical Officer, breaks down the three major categories of immunotherapy. Have you been treated with immunotherapy for #multiplemyeloma? #kNOwMyeloma Joseph Mikhael #BloodCancerAwareness #BloodCancerAwarenessMonth #BloodCancer #CancerAwareness #September #Myeloma #MultipleMyeloma #MyelomaWarrior #kNOwMyeloma #cancerresearch #cancersupport #canceradvocacy #InternationalMyelomaFoundation #CancerFacts #mmsm

Research continues to deliver new diagnostic tools and treatments in oncology, which could mean better patient outcomes and lower costs. Digital connectivity, alignment to clinical guidelines and collaborative provider relationships can help ensure patients have access to the most clinically appropriate precision testing and therapies faster, while ongoing care management can support patients throughout their journeys and reduce adverse events. Here are a few key insights from CVS Health's recent findings on costs and quality of oncology care released for #ASCO2021. #TeamCVS

What if you could identify and engage exact physicians with a biomarker positive patient within hours of a patient testing positive? Would this help increase your testing rate? Read the post below 🔽 #precisionmedicine #biomarkers

Today is the final day to register! You do not want to miss this impactful event. Join C-Path's Cure Drug Repurposing Collaboratory team and CURE ID for a groundbreaking Patient-Powered Research Webinar hosted by the Sarcoma Foundation of America, Thursday, January 18, 1 PM ET. Sarcoma Foundation of America is dedicated to fostering the development of innovative treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force, we are excited to present a pioneering project that delves into the potential of repurposing existing medications for the benefit of sarcoma patients. This initiative is at the forefront of leveraging real-world data from electronic medical records to invaluable insights shared by patients and their healthcare providers. The goal is to illuminate the path to cost-effective treatments, harnessing the power of existing drugs that, while proven safe, require further evidence to support their novel application in sarcoma therapy. Your involvement is crucial in propelling this research forward, paving the way for new, accessible treatment avenues for the sarcoma community. Learn more and register here: https://lnkd.in/gEBVyzdu. Clear Cell Sarcoma Foundation| xCures| Memorial Sloan Kettering Cancer Center| William Tap| Marco Schito| Brandi Felser| Timothy Stuhlmiller| Lennie Woods #CPath #CDRC #CUREID #drugrepurposing #sarcoma #drugdevelopment #datasharing #EHR #collaboration #globalhealth

Now more than ever, we are reminded how the safety of our ADG126 SAFEbody and its best-in-class profile is translating to better patient outcomes, including clinical response and survival. With a safety profile comparable to pembrolizumab monotherapy, the ADG126 + pembrolizumab doublet is well positioned to become a new cornerstone #IO therapy that can be broadly combined, addressing indications and patient populations beyond the IO agents available today! With its unique mechanism and ability to target CTLA-4 on Tregs in the tumor microenvironment, ADG126 is designed to take #CTLA-4 to a new level. Check out our publications showcasing its 10x higher combination dosing than ipilimumab, and unique ability to dose more frequently @Q3W and repeatedly beyond 4 cycles: https://loom.ly/m_8X16s

ICYMI: We recently released our 2023 Oncology in Diagnostic Imaging Market Outlook Report! This unique report offers a cross-modality view of the Oncology care area and provides healthcare administrators, physicians, and other diagnostic imaging professionals with the information needed to make informed decisions and plans for their facilities. Learn more about what’s included in this report by downloading the table of contents here: https://hubs.la/Q02gZgFW0

MedLever Delivers Tangible Value Every second counts in patient care. With MedLever, our partners in radiation oncology are seeing up to 75-90% improvements in task handoff times and a 35% reduction in the time between the initial consult and the first treatment. That's not just efficiency—it's better patient care. The numbers tell the story. Ready to see what MedLever can do for your clinic? Jacob Philip Ken Chiang #radonc

In the realm of healing, where hope takes flight, Losartan emerges, a beacon of light. For those with leukemia, in battles so tough, This medication’s touch makes the path less rough. It targets AGTR1, a receptor so bold, Inhibiting its power, breaking its hold. Cancer’s growth disrupted, its strength fades away, Chemotherapy’s might now holds greater sway. In men and women, the difference is clear, Survival rates rise, a tale we hold dear. Losartan’s shield guards the heart with care, In this fight for life, it stands ever fair. A promise of hope, in each patient’s eyes, With losartan’s aid, their spirits rise. A testament to science, a work of art, For leukemia patients, a hopeful start. ———— Giving cancer patients losartan could make their chemotherapy treatments more effective and protect them from potential heart damage, according to a new analysis published in Science Translational Medicine.[1]

Save the date and save your seat! 🗓️ 🩺 Healthcare Providers: Jan. 17, 2024 @ 5PM ET ctf.org/webinar 💞 Patients & Caregivers: Jan. 18, 2024 @ 8PM ET ctf.org/tunein The Children's Tumor Foundation is hosting this presentation by NFlection Therapeutics to share results from the Phase 2b Study of NFX‑179 Topical Gel in the treatment of cutaneous neurofibromas in neurofibromatosis type 1 with the NF community. #endnf #makenfvisible